Profile picture
, 5 tweets, 2 min read
My Authors
Read all threads
The data from serological tests, conducted by Thyrocare Labs on about 2.7 lakh people, shows that 26% Indians (average) have already contracted the novel coronavirus disease
newsbytesapp.com/timeline/india…
They have neutralizing antibodies in their blood, which is the immune response a body automatically generates to fight off the potentially deadly virus - Dr. A Velumani, the MD of Thyrocare Labs
The figure suggested by Dr. Velumani indicates that at least 1 in 4 Indians have already recovered from the virus and are now protected against it

In July, the company had provided an estimate of 15% but that was from a smaller sample of 53,000
If the current trend of infections-recoveries continues, 40% of India's population will have antibodies against coronavirus, Dr. Velumani projected

newsbytesapp.com/timeline/india…
Finding more immune people through these serological tests could prove useful in identifying front-line workers who can safely work around critical COVID-19 cases

It would also increase the number of people willing to donate blood for the plasma therapy of sick patients
Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with NewsBytes

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

More from @NewsBytesApp see all

Profile picture
NewsBytes
@NewsBytesApp
Hyderabad-based Bharat Biotech has been allowed to conduct a trial to test administer its COVID-19 vaccine candidate through the skin (intradermal vaccine delivery)
newsbytesapp.com/timeline/india…
The method is said to be more effective as it requires a lower dose of vaccine compared to intramuscular routes, thus lowering the per injection cost

The vaccine candidate, called COVAXIN, is already undergoing trials for intramuscular vaccine delivery
Bharat Biotech, which developing COVAXIN in collaboration with the Indian Council of Medical Research (ICMR), has now become the first Indian company to be experimenting a potential vaccine in both intradermal and intramuscular methods
Read 6 tweets
Profile picture
NewsBytes
@NewsBytesApp
A strain of the novel coronavirus that is 10 times more infectious has been found in Malaysia
newsbytesapp.com/timeline/world…
The mutated strain of SARS-CoV-2 involves a D614G mutation

The mutation changes the amino acid at position 614 from D (aspartic acid) to G (glycine)

There has been a rising prevalence of the G614 variant, which is said to be 10 times more infectious
In Malaysia, the mutation was found in at least three cases in a cluster of 45

The cluster started from a man, who is a restaurant owner, returning from India

The mutation was also detected in another cluster with people returning from the Philippines
newsbytesapp.com/timeline/world…
Read 5 tweets
Profile picture
NewsBytes
@NewsBytesApp
Earlier, it was believed that a large number of asymptomatic patients was bad news since people could infect others without knowing that they were infected

However, experts now point out that this may be a good thing

newsbytesapp.com/timeline/scien…
According to Monica Gandhi, an infectious-disease specialist at the University of California at San Francisco, asymptomatic infections may hold the key for community-wide immunity or herd immunity against SARS-CoV-2
Antibody surveys conducted so far may have found the presence of antibodies against SARS-CoV-2 in a significant portion of the population, but the number declines over time

Interestingly, these surveys have not accounted for the T cell immunity response
Read 9 tweets

Embed code for your website

×
Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!